Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

被引：59

作者：

Webers, Casper ^{[1
,2
]}

Ortolan, Augusta ^{[3
,4
]}

Sepriano, Alexandre ^{[4
,5
]}

Falzon, Louise ^{[6
]}

Baraliakos, Xenofon ^{[7
]}

Landewe, Robert B. M. ^{[8
,9
]}

Ramiro, Sofia ^{[4
,9
]}

van der Heijde, Desiree ^{[4
]}

Nikiphorou, Elena ^{[4
,10
,11
]}

机构：

[1] Maastricht Univ, Dept Internal Med, Div Rheumatol, Med Ctr, Postbus 5800, NL-6202 AZ Maastricht, Netherlands

[2] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands

[3] Univ Padua, Dept Med DIMED, Rheumatol Unit, Padua, Italy

[4] Leiden Univ, Dept Rheumatol, Med Ctr, Leiden, Netherlands

[5] Univ Nova Lisboa, NOVA Med Sch, Lisbon, Portugal

[6] Univ Sheffield, Sch Hlth & Related Res, Hlth Econ & Decis Sci, Sheffield, S Yorkshire, England

[7] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany

[8] Univ Amsterdam, Dept Clin Immunol & Rheumatol, Med Ctr, Amsterdam, Netherlands

[9] Zuyderland Med Ctr Heerlen, Dept Rheumatol, Heerlen, Netherlands

[10] Kings Coll Hosp London, Dept Rheumatol, London, England

[11] Kings Coll London, Ctr Rheumat Dis, London, England

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷 / 01期

关键词：

spondylitis; ankylosing; biological therapy; tumour necrosis factor inhibitors; axial spondyloarthritis; ACTIVE ANKYLOSING-SPONDYLITIS; MEDIATED INFLAMMATORY DISEASES; FACTOR INHIBITOR TREATMENT; ANTI-TNF AGENTS; LONG-TERM; DOUBLE-BLIND; CERTOLIZUMAB PEGOL; OPEN-LABEL; ETANERCEPT TREATMENT; CONSENSUS STATEMENT;

D O I：

10.1136/ard-2022-223298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective To update the evidence on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2022 update of the Assessment of SpondyloArthritis international Society/European Alliance of Associations for Rheumatology (ASAS-EULAR) recommendations for the management of axSpA. Methods Systematic literature review (2016-2021) on efficacy and safety of bDMARDs in axSpA (radiographic axSpA (r-axSpA)/non-radiographic axSpA (nr-axSpA)). Eligible study designs included randomised controlled trials (RCTs), strategy trials and observational studies (the latter only for safety and extra-musculoskeletal manifestations). All relevant efficacy/safety outcomes were included. Results In total, 148 publications were included. Efficacy of golimumab and certolizumab was confirmed. Tumour necrosis factor inhibitor (TNFi) biosimilar-originator equivalence was demonstrated. RCT (n=15) data on efficacy of interleukin-17 inhibitors (IL-17i) demonstrated clinically relevant effects (risk ratio vs placebo to achieve ASAS40 response 1.3-15.3 (r-axSpA, n=9), 1.4-2.1 (nr-axSpA, n=2)). Efficacy of secukinumab/ixekizumab was demonstrated in TNFi-naive and TNFi-inadequate responders. IL-23 and IL-12/23 inhibitors (risankizumab/ustekinumab) failed to show relevant benefits. Tapering of TNFi by spacing was non-inferior to standard-dose treatment. The first axSpA treat-to-target trial did not meet its primary endpoint, but showed improvements in secondary outcomes. No new risks were identified with TNFi use in observational studies (data lacking for IL-17i). Secukinumab (n=1) and etanercept (n=2) were associated with increased risk of uveitis in observational studies compared to monoclonal TNFi. Conclusions New evidence supports the efficacy and safety of TNFi (originators/biosimilars) and IL-17i in r-axSpA and nr-axSpA, while IL-23i failed to show relevant effects. Observational studies are needed to confirm long-term IL-17i safety. PROSPERO registration number CRD42021257588

引用

页码：130 / 141

页数：12

共 95 条

[1] IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong? [J].

Baeten, Dominique ;

Adamopoulos, Iannis E. .

FRONTIERS IN IMMUNOLOGY, 2021, 11

[2] Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study [J].

Baeten, Dominique ;

Ostergaard, Mikkel ;

Wei, James Cheng-Chung ;

Sieper, Joachim ;

Jarvinen, Pentti ;

Tam, Lai-Shan ;

Salvarani, Carlo ;

Kim, Tae-Hwan ;

Solinger, Alan ;

Datsenko, Yakov ;

Pamulapati, Chandrasena ;

Visvanathan, Sudha ;

Hall, David B. ;

Aslanyan, Stella ;

Scholl, Paul ;

Padula, Steven J. .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (09) :1295-1302

[3] Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study [J].

Baraliakos, Xenofon ;

Braun, Juergen ;

Deodhar, Atul ;

Poddubnyy, Denis ;

Kivitz, Alan ;

Tahir, Hasan ;

Van den Bosch, Filip ;

Delicha, Evie-Maria ;

Talloczy, Zsolt ;

Fierlinger, Anke .

RMD OPEN, 2019, 5 (02)

[4] Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial [J].

Behrens, Frank ;

Sewerin, Philipp ;

de Miguel, Eugenio ;

Patel, Yusuf ;

Batalov, Anastas ;

Dokoupilova, Eva ;

Kleinmond, Christine ;

Pournara, Effie ;

Shekhawat, Ankita ;

Jentzsch, Claudia ;

Wiedon, Annette ;

Baraliakos, Xenofon .

RHEUMATOLOGY, 2022, 61 (07) :2856-2866

[5] CLINICAL EFFECTIVENESS OF ADALIMUMAB VERSUS NON-BIOLOGIC THERAPY IN THE MANAGEMENT OF EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS PATIENTS OVER 24 MONTHS - RESULTS OF THE COMPLETE-AS CANADIAN OBSERVATIONAL STUDY [J].

Bessette, L. ;

Haraoui, B. ;

Florica, B. ;

Laliberte, M. C. ;

Khraishi, M. .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 :336-337

[6] First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis [J].

Braun, J ;

Davis, J ;

Dougados, M ;

Sieper, J ;

van der Linden, S ;

van der Heijde, D .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (03) :316-320

[7] International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis [J].

Braun, J ;

Pham, T ;

Sieper, J ;

Davis, J ;

van der Linden, S ;

Dougados, M ;

van der Heijde, D .

ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :817-824

[8] 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis [J].

Braun, J. ;

van den Berg, R. ;

Baraliakos, X. ;

Boehm, H. ;

Burgos-Vargas, R. ;

Collantes-Estevez, E. ;

Dagfinrud, H. ;

Dijkmans, B. ;

Dougados, M. ;

Emery, P. ;

Geher, P. ;

Hammoudeh, M. ;

Inman, R. D. ;

Jongkees, M. ;

Khan, M. A. ;

Kiltz, U. ;

Kvien, T. K. ;

Leirisalo-Repo, M. ;

Maksymowych, W. P. ;

Olivieri, I. ;

Pavelka, K. ;

Sieper, J. ;

Stanislawska-Biernat, E. ;

Wendling, D. ;

Ozgocmen, S. ;

van Drogen, C. ;

van Royen, B. J. ;

van der Heijde, D. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :896-904

[9] Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data [J].

Cansu, Dondu Uskudar ;

Teke, Hava Uskudar ;

Temel, Tuncer ;

Erturk, Adem ;

Kahraman, Osman ;

Korkmaz, Cengiz .

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2019, 111 (03) :262-269

[10] Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study [J].

Cantini, Fabrizio ;

Niccoli, Laura ;

Cassara, Emanuele ;

Kaloudi, Olga ;

Nannini, Carlotta .

BIOLOGICS-TARGETS & THERAPY, 2013, 7 :1-6

← 1 2 3 4 5 6 7 8 9 10 →